Growth and quality of life after living-related liver transplantation in children.

摘要: Fifty-six consecutive pediatric recipients surviving more than 3 yr after living-related liver transplantation (LRLT) were evaluated in terms of growth, quality life (QOL) and need for maintenance immunosuppression. Significant improvement Z-score height weight observed at last follow-up, ranging from to 6 transplantation, although catchup gain lagged behind recovery (height: -1.77 pre-transplant -0.77 post-transplant, p<0.001; weight: -1.12 -0.18 p<0.0001). 82% (46) have remained good health an excellent QOL as assessed the most recent months; these children lead similar daily lives normal healthy children, with school attendance full participation activities including gymnastics hiking. 3.6% (2) attended regularly but unable participate sporting activities. 14% (8) remain home or hospital-bound due persistent complications past months, only minimal attendance. Less 10% taking steroids by 2 post-transplantation, approximately half receiving low-dose 1 yr. The mainstay immunosuppressant was tacrolimus, 68% (38) therapy, 8.9% (5) alternate-day, twice a week, 5.4% (3) single dose weekly alternate weeks. 7.1% (4) withdrawn completely all immunosuppressants, various reasons. patients needed multiple immunosuppressive agents over months. In conclusion, LRLT restores growth offers recipients. majority require minimal, steroid-free, immunosuppression occasional recipient still needs intensive longterm